-
Signature
-
/s/ James Pennington, Attorney-in-Fact
-
Issuer symbol
-
JANX
-
Transactions as of
-
28 Oct 2025
-
Net transactions value
-
-$388,298
-
Form type
-
4
-
Filing time
-
30 Oct 2025, 20:00:05 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Meyer Andrew Hollman |
Chief Business Officer |
C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO |
/s/ James Pennington, Attorney-in-Fact |
30 Oct 2025 |
0001864159 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
JANX |
Common Stock |
Options Exercise |
$42,096 |
+9,999 |
+12% |
$4.21 |
92,138 |
28 Oct 2025 |
Direct |
|
| transaction |
JANX |
Common Stock |
Options Exercise |
$70,593 |
+6,666 |
+7.2% |
$10.59 |
98,804 |
28 Oct 2025 |
Direct |
|
| transaction |
JANX |
Common Stock |
Sale |
$500,987 |
-16,665 |
-17% |
$30.06 |
82,139 |
28 Oct 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
JANX |
Stock Option (right to buy) |
Options Exercise |
$0 |
-9,999 |
-11% |
$0.000000 |
77,333 |
28 Oct 2025 |
Common Stock |
9,999 |
$4.21 |
Direct |
F3 |
| transaction |
JANX |
Stock Option (right to buy) |
Options Exercise |
$0 |
-6,666 |
-5.2% |
$0.000000 |
121,434 |
28 Oct 2025 |
Common Stock |
6,666 |
$10.59 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: